The vice president for science and technology affairs stated: this year, we have a detailed program for supplying the required drugs of the country by the help of knowledge-based companies active in this area. Due to the current condition of Iran and limitations imposed on our country, knowledge-based companies are determined to supply the essential drug needs of the country.

According to the public relations and information center of the Vice-Presidency for science and technology affairs, the anticancer drug produced by domestic technologies was unveiled on May 7^th, 2019 in the presence of the vice president for science and technology affairs, the minister of health, and the governor of Alborz Province.

We Will Bring Currency with Our Drugs

The vice president for science and technology affairs described the detailed program for supplying primary pharmaceutical materials and technology for production of exported drug goods, expressing: knowledge-based companies and accelerators active in this field have provided a potential capacity for meeting the needs of the country and lack of need for export of drugs. Without a doubt, the drug-producing companies of Iran have a hidden capacity, which can be used to meet a significant part of our needs and bring currency by exporting our drugs to other countries.

The president of the knowledge-based economy, technology and science development headquarter pointed out the capable and advanced ecosystem of Alborz drug companies, affirming: we have the capacity to turn Alborz into a drug pole due to its human capital and equipment.

The vice president for science and technology affairs announced the supply of sanctioned drug goods with the help of the ministry of health and by relying on the abilities of knowledge-based companies, adding: with regard to the current conditions of the country and limitations in this field, knowledge-based companies are determined to move toward producing essential drugs and sanctioned goods. As observed, despite the fact that a short time has passed since the conclusion of contracts, these companies have been able to present drugs to the market in a short time.

Lack of Need for Import of Cancer and Antidiabetic Drugs

A small number of drug companies in Iran and the world are capable in the field of anticancer drugs. In this regard, the knowledge-based company of Danesh Kimia Pharmed (DAKFA) is one of the domestic knowledge-based companies that have taken steps toward the production and domestication of these drugs with the cooperation of its subsidiary companies, including Alborz Farmed, Baran and Danesh.

Today, this knowledge-based company is on the path of establishing Baran Drug Accelerator with the support of startups in the field of drug production supported by the Vice-Presidency.

“Regorafenib” is one of the drugs produced by this Iranian knowledge-based company, which is used in the treatment of metastatic verructal cancers and metastatic intestinal ulcerative tumors, or those with a non-surgical tumor that are immune to sunitinib and imatinib. In addition, the drug has applications for patients with liver cell carcinoma.

“Sorafenib” is another anticancer drug for non-surgical hepatocellular liver cells, advanced renal cell cancer, and iodine-resistant thyroid cancer.

The antidiabetic drug of “Empagliflozin” is another medicine that reduces the mortality rate in adults with type-II diabetes.

The technical knowledge for production of these drugs is owned by Germany and the United States, and Iran is the third producer of this drug in the world.

The antidiabetic drug of “dapagliflozin” is a newly produced drug, which is applied to treat type-II diabetes. After the United Kingdom, Iran is the second country that has been able to produce this medicine.

These drugs are categorized as type II sodium-glucose-receptor antagonist drugs. Iran has been able to produce two drugs that were presented in the market by 2014 during five years. Moreover, these drugs are among the most applicable medications.